Skip to main content
. 2022 Nov 30;14(12):2664. doi: 10.3390/pharmaceutics14122664

Table 3.

Pharmacokinetic parameters after the oral administration of NFT formulations.

Tmax a (h) Cmax b (ng/mL) AUC0-8h b (ng·h/mL) AUC0-∞ b (ng·h/mL) t1/2 b (h)
PM 0.50 177 ± 75 438 ± 153 483 ± 142 2.6 ± 0.8
PVPVA ASD 0.50 130 ± 83 345 ± 176 664 ± 354 9.1 ± 10.0
HPMAS ASD 0.50 132 ± 49 475 ± 152 555 ± 200 2.7 ± 0.3
Eudragit ASD 1.0 232 ± 84 590 ± 163 685 ± 168 2.8 ± 0.8

a median, b mean ± SD.